Colon cancer comprises a small population of cancer initiating stem cells (CIC) that is responsible for tumor maintenance and resistance to anti-cancer therapies, possibly allowing for tumor recapitulation once treatment stops. Combinations of immune-based therapies with chemotherapy and other anti-tumor agents may be of significant clinical benefit in the treatment of colon cancer. However, cellular immune-based therapies have not been experimented yet in the population of colon CICs. Here, we demonstrate that treatment with low concentrations of commonly used chemotherapeutic agents, 5-fluorouracyl and doxorubicin, sensitize colon CICs to Vγ9Vδ2 T cell cytotoxicity. Vγ9Vδ2 T cell cytotoxicity was largely mediated by TRAIL interaction with DR5, following NKG2D-dependent recognition of colon CIC targets. We conclude that in vivo activation of Vγ9Vδ2 T cells or adoptive administration of ex-vivo expanded Vγ9Vδ2 T cells at suitable intervals after chemotherapy may substantially increase anti-tumor activities and represent a novel strategy for colon cancer immunotherapy.

Todaro, M., Orlando, V., Cicero, G., Caccamo, N., Meraviglia, S., Stassi, G., et al. (2013). Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells. ONCOIMMUNOLOGY, 8, 00-00 [10.1371/journal.pone.0065145.].

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells.

TODARO, Matilde;CICERO, Giuseppe;CACCAMO, Nadia Rosalia;MERAVIGLIA, Serena;STASSI, Giorgio;DIELI, Francesco
2013-01-01

Abstract

Colon cancer comprises a small population of cancer initiating stem cells (CIC) that is responsible for tumor maintenance and resistance to anti-cancer therapies, possibly allowing for tumor recapitulation once treatment stops. Combinations of immune-based therapies with chemotherapy and other anti-tumor agents may be of significant clinical benefit in the treatment of colon cancer. However, cellular immune-based therapies have not been experimented yet in the population of colon CICs. Here, we demonstrate that treatment with low concentrations of commonly used chemotherapeutic agents, 5-fluorouracyl and doxorubicin, sensitize colon CICs to Vγ9Vδ2 T cell cytotoxicity. Vγ9Vδ2 T cell cytotoxicity was largely mediated by TRAIL interaction with DR5, following NKG2D-dependent recognition of colon CIC targets. We conclude that in vivo activation of Vγ9Vδ2 T cells or adoptive administration of ex-vivo expanded Vγ9Vδ2 T cells at suitable intervals after chemotherapy may substantially increase anti-tumor activities and represent a novel strategy for colon cancer immunotherapy.
2013
Todaro, M., Orlando, V., Cicero, G., Caccamo, N., Meraviglia, S., Stassi, G., et al. (2013). Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells. ONCOIMMUNOLOGY, 8, 00-00 [10.1371/journal.pone.0065145.].
File in questo prodotto:
File Dimensione Formato  
Todaro et al Oncoimmunology 2013.pdf

accesso aperto

Dimensione 195.45 kB
Formato Adobe PDF
195.45 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/100602
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 31
social impact